New Dual-Energy catheter aims to stop deadly heart rhythms
NCT ID NCT06816368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new catheter that uses two types of energy (radiofrequency and pulsed field) to destroy the tiny areas of heart tissue causing ventricular tachycardia, a fast and dangerous heart rhythm. Thirty patients with recurrent episodes will undergo the procedure. The goal is to see if the new technology can safely eliminate the abnormal rhythms during the procedure and prevent them from coming back for at least six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
catheter ablation using radiofrequency and pulsed field energy
What this could lead to
If successful, this could offer a more effective and safer way to control ventricular tachycardia, reducing the need for repeated procedures.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to everyone. There are risks of complications like bleeding or heart damage from the ablation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA (V-TACH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IUCPQ
Québec, Quebec, Canada
-
McGill University Health Centre
Montreal, Quebec, Canada
-
Montreal Heart Institute
Montreal, Quebec, Canada